A22.1 Pulmonary anthrax

Name of the Condition

• Pulmonary anthrax (ICD-10-CM Code: A22.1)

Summary

Pulmonary anthrax is a rare but severe bacterial infection of the respiratory system caused by Bacillus anthracis. It results from inhaling spores and can progress rapidly to systemic illness if not treated promptly. The condition requires immediate medical intervention to prevent life-threatening complications.

Causes

Pulmonary anthrax is caused by the spore-forming bacterium Bacillus anthracis. Infection occurs when spores are inhaled, typically from contaminated animal products, soil, or aerosolized particles. Spores can remain viable in the environment for extended periods, enabling exposure even after the source is no longer active.

Risk Factors

• Occupational exposure to livestock or animal byproducts (e.g., farmers, veterinarians, tannery workers).
• Handling or processing animal hides, wool, or bone meal from endemic regions.
• Inhalation of spores in environments with contaminated soil or animal remains.
• Exposure to aerosolized spores in laboratory or bioterrorism-related settings.

Symptoms

• Initial: Flu-like symptoms (fever, cough, chest discomfort) resembling a common cold or influenza.
• Progression: Severe respiratory distress, difficulty breathing, and shock as the infection advances.
• Systemic signs: High fever, sweating, and confusion may develop as the disease spreads.

Diagnosis

Diagnosis is confirmed through a combination of clinical evaluation, imaging (e.g., chest X-rays or CT scans showing characteristic findings), and laboratory testing. Samples of blood, respiratory secretions, or tissue may be cultured or tested for Bacillus anthracis DNA. Early recognition is critical due to the rapid progression of the disease.

Treatment Options

• Immediate administration of intravenous antibiotics (e.g., ciprofloxacin, doxycycline) is essential.
• Supportive care, including oxygen therapy and management of shock, may be required.
• Antitoxin therapy may be used in severe cases to neutralize bacterial toxins.

Prognosis and Follow-Up

Prognosis depends on the timeliness of treatment; delays significantly increase the risk of death. Survivors require close monitoring for respiratory complications and systemic involvement. Follow-up care focuses on assessing lung function and managing any long-term effects of the infection.

Complications

• Respiratory failure and acute respiratory distress syndrome (ARDS).
• Septic shock and multi-organ failure.
• Meningitis or other systemic infections if the bacteria spread to the central nervous system.

Lifestyle & Prevention

• Avoid handling or processing animal products from regions with known anthrax outbreaks.
• Use appropriate protective equipment (e.g., masks, gloves) in high-risk occupational settings.
• Ensure proper ventilation and safety measures in environments where spore exposure is possible.
• Do not consume undercooked meat from potentially infected animals.

When to Seek Professional Help

Seek immediate medical attention if you experience sudden flu-like symptoms (fever, cough, chest pain) after potential exposure to anthrax spores, especially in high-risk settings. Early treatment is critical to improve outcomes.

Tips for Medical Coders

• Code A22.1 is specific to pulmonary anthrax and should be used when the infection is confirmed to involve the respiratory system.
• Documentation should specify the route of exposure (inhalation) and any associated symptoms or complications to support the diagnosis.
• Ensure the code aligns with clinical findings and laboratory confirmation of Bacillus anthracis infection.